

Table S2. Associations between number of somatic mutations in *TP53* gene and outcomes in patients with advanced ovarian cancer (All, n=79), including HGSOCs (HGSOC, n=64).

		Median survival		Univariate			Multivariate ^a		
		n. of patients	time (months)	HR [*]	95% CI [*]	<i>p</i> [*]	HR [*]	95% CI [*]	<i>p</i> [*]
All (n=79)									
PFI^a									
	N. of <i>TP53</i> mutations								
0		21	22.1	Ref.	-	-	Ref.	-	-
≥1		56	8.2	1.53	0.89-2.65	0.125	1.70	0.91-3.21	0.098
TTR^a									
	N. of <i>TP53</i> mutations								
0		21	28.2	Ref.	-	-	Ref.	-	-
≥1		56	13.8	1.50	0.85-2.63	0.160	1.65	0.86-3.15	0.128
OS									
	N. of <i>TP53</i> mutations								
0		22	68.3	Ref.	-	-	Ref.	-	-
≥1		57	44.0	1.58	0.81-3.08	0.180	1.65	0.76-3.54	0.203
HGSOC (n=64)									
PFI^b									
	N. of <i>TP53</i> mutations								
0		15	15.7	Ref.	-	-	Ref.	-	-
≥1		48	8.2	1.23	0.68-2.24	0.495	1.46	0.74-2.89	0.277
TTR^b									
	N. of <i>TP53</i> mutations								
0		15	20.3	Ref.	-	-	Ref.	-	-
≥1		48	13.8	1.17	0.62-2.20	0.619	1.37	0.67-2.79	0.391
OS									
	N. of <i>TP53</i> mutations								
0		15	71.1	Ref.	-	-	Ref.	-	-
≥1		49	45.1	1.41	0.59-3.35	0.435	1.60	0.65-3.94	0.303

^aEstimated through Cox proportional hazard model; ^{*}Adjusted for residual tumor after PDS, FIGO stage and age at diagnosis. ^aTwo patients were not evaluated due to loss at follow up. ^bOne patient was not evaluated due to loss of follow-up. Ref.: Reference Category; PFI: platinum free interval; TTR: time to recurrence; OS: overall survival.